EN
Clarification Statement
SINOVAC Biotech Ltd. ("SINOVAC") recently noticed a Portuguese-language press release with a statement that does not conform to the facts. This fraudulent statement ("Fraudulent Statement") was published by certain media outlets in Brazil on 16 July 2021, claiming that "the World Brands S.A. and individuals can purchase from SINOVAC Biotech Ltd." which was fake. Several media have reported about the Fraudulent Statement.
With regard to this, we hereby clarify that:
(i) the Covid-19 vaccine (CoronaVac®) is developed, manufactured and distributed by SINOVAC Life Sciences Co., Ltd.
(ii) In Brazil, only the Instituto Butantan, our exclusive partner, can purchase CoronaVac®. We have been working hard with the Instituto Butantan to provide affordable vaccines to the Brazilian people.
(iii) Any information released by any company without authorization from SINOVAC has no legal significance.
(iv) For illegal acts of publishing fake news, we reserve the right to take all actions, including taking legal actions, seeking remedies and seeking accountability.
SINOVAC Biotech Ltd.
Jul 17, 2021
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of "supply vaccines to eliminate human diseases", the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.
The company's diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.
SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world's first inactivated SARS vaccine (Phase I completed), China's first H5N1 influenza vaccine (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.
Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines,recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.
With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.
For more information, please see the Company’s website at www.sinovac.com.